Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Ultrasound Obstet Gynecol. 2024 Mar;63(3):342-349. doi: 10.1002/uog.27462.
To describe the distributional properties and assess the performance of placental growth factor (PlGF) measured in blood samples collected before 11 weeks' gestation in the prediction of pre-eclampsia (PE).
The study population consisted of pregnant women included in the Pre-eclampsia Screening in Denmark (PRESIDE) study with a PlGF measurement from the routine combined first-trimester screening (cFTS) blood sample collected at 8-14 weeks' gestation. PRESIDE was a prospective multicenter study investigating the predictive performance of the Fetal Medicine Foundation (FMF) first-trimester screening algorithm for PE in a Danish population. In the current study, serum concentration of PlGF in the cFTS blood samples was analyzed in batches between January and June 2021.
A total of 8386 pregnant women were included. The incidence of PE was 0.7% at < 37 weeks' gestation and 3.0% at ≥ 37 weeks. In blood samples collected at 10 weeks' gestation, PlGF multiples of the median (MoM) were significantly lower in pregnancies with preterm PE < 37 weeks compared to unaffected pregnancies. However, PlGF MoM did not differ significantly between pregnancies with PE and unaffected pregnancies in samples collected before 10 weeks' gestation.
The gestational-age range for PlGF sampling may be expanded from 11-14 to 10-14 weeks when assessing the risk for PE using the FMF first-trimester screening model. There is little evidence to support the use of PlGF in blood samples collected before 10 weeks' gestation. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
描述胎盘生长因子（PlGF）在 11 周妊娠前的血样中的分布特征，并评估其在预测子痫前期（PE）中的表现。
研究人群为参与丹麦子痫前期筛查（PRESIDE）研究的孕妇，这些孕妇在 8-14 周妊娠时接受了常规的联合早孕期筛查（cFTS），并进行了 PlGF 检测。PRESIDE 是一项前瞻性多中心研究，旨在调查胎儿医学基金会（FMF）的早孕期筛查算法在丹麦人群中预测 PE 的性能。在本研究中，于 2021 年 1 月至 6 月间分批次分析了 cFTS 血样中的 PlGF 血清浓度。
共纳入 8386 名孕妇。妊娠<37 周时的 PE 发生率为 0.7%，妊娠≥37 周时的 PE 发生率为 3.0%。在 10 周妊娠时采集的血样中，与无 PE 的妊娠相比，早产 PE<37 周的妊娠 PlGF 中位数倍数（MoM）显著降低。然而，在 10 周妊娠前采集的血样中，PE 妊娠与无 PE 的妊娠之间 PlGF MoM 无显著差异。
当使用 FMF 早孕期筛查模型评估 PE 风险时，PlGF 采样的妊娠周数范围可能从 11-14 周扩展到 10-14 周。在 10 周妊娠前采集的血样中，几乎没有证据支持使用 PlGF。© 2023 作者。超声在妇产科由约翰威立父子有限公司代表国际妇产科超声学会出版。
